I'd call the secondary endpoints coincidental to the fact that a huge boost in HDL got essentially nothing in interarterial plague volume reduction and a negative effect on arterial thickness.
It's a class effect.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC